<tr>
    <td>
        <table style="background-color:#dfe5e6;border:1px solid #558476;font-family: Arial;border-collapse: collapse" width="550">
            <tr>
                <td width="500" style="padding: 15px 25px 10px;">
                    <p style="font-size:26px;font-weight:bold;color:#558476;margin-bottom: 0px;">Acute lymphoblastic leukemia (ALL) is a challenging disease state</p>
                    <p style="font-size:16px;font-weight:bold;color:#333333;margin-bottom: 3px;">
                        Adult B-ALL is a rare and serious disease<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">{{CitationNumber[1]}}</sup>
                    </p>
                    <table style="font-family: arial; font-size: 16px; border-collapse: collapse" width="500" border="0">
                        <tr>
                            <td style="color:#558476; vertical-align: top">&#x25cf;</td>
                            <td style="line-height: 1.333;">There are around 6,070 case of ALL diagnosed annually in the US<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">{{CitationNumber[2]}}</sup></td>
                        </tr>
                        <tr>
                            <td style="color:#558476; vertical-align: top">&#x25cf;</td>
                            <td>Most cases have an unknown etiology<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">{{CitationNumber[1]}}</sup>
                            </td>
                        </tr>
                    </table>
                    <p style="font-size:16px;font-weight:bold;color:#333333;margin-bottom: 3px;">
                        About 80% to 90% of previously untreated patients will achieve complete remission, but 44% of these patients will relapse<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">{{CitationNumber[1]}},{{CitationNumber[3]}}</sup>
                    </p>
                    <table style="font-family: arial; font-size: 16px;" width="500" border="0">
                        <tr>
                            <td style="color:#558476; vertical-align: top">&#x25cf;</td>
                            <td style="line-height: 1.333;">The standard treatment for relapsed B-ALL is to induce a second complete remission with salvage therapy and then proceed to hematopoietic stem cell transplantation therapy<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">{{CitationNumber[4]}}</sup></td>
                        </tr>
                    </table>
                    <p style="font-size:16px;font-weight:normal;color:#333333;font-style:italic;text-align:center;padding: 0">
                        The NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL.<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">{{CitationNumber[5]}}</sup>
                    </p>
                    <table style="margin-bottom:12px;border-collapse: collapse;font-family: Arial;">
                        <tr style="background:white;">
                            <td style="padding: 12px 20px; font-family: Arial">
                                <b style="font-size:16px !important;">ALL is difficult to manage<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">{{CitationNumber[6]}},{{CitationNumber[7]}}</sup></b>
                                <table style="font-size: 16px;" border="0" style="border-collapse: collapse;font-family: Arial;">
                                    <tr>
                                        <td style="color:#558476; vertical-align: top">&#x25cf;</td>
                                        <td style="line-height: 1.333; font-family: arial;">B-ALL patients have a complex range of genetic abnormalities that influence outcomes and response</td>
                                    </tr>
                                    <tr>
                                        <td style="color:#558476; vertical-align: top">&#x25cf;</td>
                                        <td style="line-height: 1.333; font-family: arial;">A variety of genetic mutations are likely to be involved in the pathogenesis of B-ALL</td>
                                    </tr>
                                </table>
                            </td>
                        </tr>
                    </table>
                    <table  cellspacing="0" cellpadding="0" bgcolor="#558476" align="center" style=";margin:0px auto">
                        
                        <tr><td align="center" style="font-family: arial; padding:15px;padding-bottom:15px"> <a href="http://www.understandingall.com/index.html" target="_blank" style="font-size:22px;color:#eece11;text-decoration:none;vertical-align:middle;"><strong>Find out more about adult ALL &gt; </strong></a></td></tr>
                    </table>
                   
                </td>
            </tr>
        </table>
    </td>
</tr>
{{CitationStart}}
<br><strong>{{CitationNumber[1]}}.</strong> Jain N, Gurbuxani S, Rhee C, Stock W. In: Hoffman R, Benz EJ Jr, Silbertein LE, Heslop H, Weitz J, Anastasi J, eds. <em>Hematology: Basic Principles and Practice.</em> 6th ed. Philadelphia, PA: Saunders-Elsevier; 2013:960-980.
<br><strong>{{CitationNumber[2]}}.</strong> Siegel R, Naishadham D, Jemal A. <em>CA Cancer J Clin.</em> 2013;63:11-30.
<br><strong>{{CitationNumber[3]}}.</strong> Heeler D. <em>Am Soc Clin Oncol Educ Book.</em> 2013;290-293.
<br><strong>{{CitationNumber[4]}}.</strong> Forman SJ, Rowe JM. <em>Blood.</em> 2013;121:1077-1082.
<br><strong>{{CitationNumber[5]}}.</strong> References with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup>) for Acute Lymphoblastic Leukemia V.1.2014. Â© National Comprehensive Cancer Network, Inc 2014. All rights reserved. Accessed July 8, 2014. To view the most recent and complete version of the guidelines, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup>, NCCN<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup>, NCCN GUIDELINES<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup>, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
<br><strong>{{CitationNumber[6]}}.</strong> Pui CH, Relling MV, Downing JR. <em>N Engl J Med.</em> 2004;350:1535-1548.
<br><strong>{{CitationNumber[7]}}.</strong> Zhou Y, You MJ, Young KH, et al. <em>Hum Pathol.</em> 2012;43:1347-1362.
{{CitationEnd}}
